NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
YI
111, Inc.
There isn't enough reported data to score YI yet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
YI Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Under pressure | |
| Strong |
YI's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
YI PE Valuation
YI has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
YI Forward outlook
There aren't enough analyst estimates for YI to show an outlook.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over YI on earnings quality, reporting a profit while its opponent remains loss making.
YI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.79 | -$0.51 |
| Q1 2026 | -$1.46 | -$0.27 |
| Q4 2025 | -$1.14 | -$0.01 |
| Q3 2025 | -$1.21 | +$3.29 |
| Q2 2025 | -$1.28 | +$4.58 |
| Q1 2025 | -$1.19 | +$5.45 |
| Q4 2024 | -$1.13 | +$5.84 |
| Q3 2024 | -$4.50 | +$0.68 |
YI is still losing money, but far less than before: $1.79 per share over the past year, against $12.49 at its worst in late 2021.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over YI on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over YI on profitability, with a higher operating margin.
YI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $345.2M | -28% |
| Q1 2026 | $354.4M | -33% |
| Q4 2025 | $417.4M | -28% |
| Q3 2025 | $450.3M | -17% |
| Q2 2025 | $481.1M | -6.4% |
| Q1 2025 | $529.6M | 0% |
| Q4 2024 | $577.4M | -6.3% |
| Q3 2024 | $540.4M | -1.8% |
YI's revenue has slid since its 2022 peak: $345M last quarter, down 28% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -1% | -1 points |
| Q1 2026 | -0.8% | -0.8 points |
| Q4 2025 | -0.2% | 0 points |
| Q3 2025 | -0.1% | -0.2 points |
| Q2 2025 | 0% | -0.1 points |
| Q1 2025 | 0% | -0.1 points |
| Q4 2024 | -0.2% | +4.8 points |
| Q3 2024 | 0.1% | +2.3 points |
YI's operating margin was −1% last quarter, down 1 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over YI on cash generation, producing positive trailing cash flow while its opponent burns cash.
YI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$1.7M | +$7.5M |
| Q1 2026 | -$13.8M | -181% |
| Q4 2025 | $3.8M | +$13.4M |
| Q3 2025 | $5.7M | -65% |
| Q2 2025 | -$9.2M | -166% |
| Q1 2025 | $16.9M | +3.8% |
| Q4 2024 | -$9.6M | +$21.5M |
| Q3 2024 | $16.5M | +212% |
YI has burned cash in most quarters: −$6M over the past year, against $15M the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over YI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
YI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +28.3K shares |
| 1 year | +1.7% | +145K shares |
| 3 years | +5% | +418K shares |
| 5 years | +6.4% | +533K shares |
| Available history | +7.5% | +615K shares |
YI has 9M diluted shares, up 1.7% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $2M |
| Q3 2024 | — |
YI hasn't bought back shares in the past year.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
YI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2025 | -22.3x | Net Cash |
| Q3 2025 | -14.5x | Net Cash |
| Q2 2025 | -14.1x | Net Cash |
| Q1 2025 | -14.0x | Net Cash |
| Q4 2024 | -8.4x | Net Cash |
YI has more cash than debt.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
YI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 27.5 | Oversold |
| Stochastic | 13.2 | Oversold |
YI's weekly RSI is 28 (oversold) and its Stochastic is 13 (oversold).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
YI PE vs Healthcare Sector
YI has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has stronger trend alignment. NVO is above 1 of 5 weekly averages versus YI above 0 of 4.
YI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.07 | 7.2% below |
| 20 week MA | $3.47 | 18% below |
| 50 week MA | $4.79 | 41% below |
| 100 week MA | $5.76 | 51% below |
YI is in a downtrend: it's below all four of its weekly moving averages, and 51% below its 100-week average.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.
YI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $11.6 | $7.35 | -36% |
| 2025 | $7.35 | $3.08 | -58% |
| 2026 YTD | $3.08 | $2.85 | -7.5% |
YI has the edge over NVO on returns for 2026, with the stronger performance.